Gary Hattersley

5.3k total citations · 1 hit paper
65 papers, 4.1k citations indexed

About

Gary Hattersley is a scholar working on Oncology, Molecular Biology and Orthopedics and Sports Medicine. According to data from OpenAlex, Gary Hattersley has authored 65 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 29 papers in Molecular Biology and 28 papers in Orthopedics and Sports Medicine. Recurrent topics in Gary Hattersley's work include Bone health and treatments (30 papers), Bone health and osteoporosis research (26 papers) and Bone Metabolism and Diseases (22 papers). Gary Hattersley is often cited by papers focused on Bone health and treatments (30 papers), Bone health and osteoporosis research (26 papers) and Bone Metabolism and Diseases (22 papers). Gary Hattersley collaborates with scholars based in United States, United Kingdom and Netherlands. Gary Hattersley's co-authors include T.J. Chambers, Vicki Rosen, Lorraine A. Fitzpatrick, Ming‐yi Hu, Paul D. Miller, Felicia Cosman, Gregory C. Williams, Anthony Celeste, Neil M. Wolfman and J. Owens and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Investigation.

In The Last Decade

Gary Hattersley

65 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

2016 581 citations Paul D. Miller, Gary Hattersley et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Hattersley United States	31	2.3k	2.0k	1.9k	842	465	65	4.1k
Michael S. Ominsky United States	41	3.9k 1.7×	2.9k 1.4×	2.8k 1.5×	669 0.8×	992 2.1×	88	6.3k
Hong‐Lin Tan United States	12	3.9k 1.7×	1.2k 0.6×	2.9k 1.5×	358 0.4×	415 0.9×	15	5.3k
G R Mundy United States	26	2.1k 0.9×	512 0.3×	2.2k 1.1×	289 0.3×	260 0.6×	51	3.8k
Lee Ann Baldridge United States	29	1.5k 0.6×	467 0.2×	915 0.5×	793 0.9×	235 0.5×	48	3.3k
Jian Q. Feng United States	17	2.0k 0.9×	706 0.3×	959 0.5×	212 0.3×	300 0.6×	27	2.8k
Noriyoshi Kurihara United States	37	2.4k 1.0×	580 0.3×	2.2k 1.1×	225 0.3×	456 1.0×	106	4.3k
Tatsuo Suda Japan	13	3.4k 1.5×	870 0.4×	2.5k 1.3×	273 0.3×	326 0.7×	14	4.5k
Kazuki Yano Japan	18	6.2k 2.7×	1.8k 0.9×	4.6k 2.4×	462 0.5×	378 0.8×	26	7.7k
Su‐Li Cheng United States	32	2.4k 1.0×	351 0.2×	682 0.4×	478 0.6×	732 1.6×	53	4.4k
Rajaram Gopalakrishnan United States	29	1.7k 0.7×	388 0.2×	982 0.5×	264 0.3×	272 0.6×	80	3.1k

Countries citing papers authored by Gary Hattersley

Since Specialization

Citations

This map shows the geographic impact of Gary Hattersley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Hattersley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Hattersley more than expected).

Fields of papers citing papers by Gary Hattersley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Hattersley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Hattersley. The network helps show where Gary Hattersley may publish in the future.

Co-authorship network of co-authors of Gary Hattersley

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Hattersley. A scholar is included among the top collaborators of Gary Hattersley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Hattersley. Gary Hattersley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Hitisha, et al.. (2023). Abstract 6264: NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts. Cancer Research. 83(7_Supplement). 6264–6264. 4 indexed citations

Lanske, Beate, Heidi Chandler, Allen R. Pierce, et al.. (2019). Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture. Journal of Orthopaedic Research®. 37(4). 812–820. 19 indexed citations

Chandler, Heidi, Daniel J. Brooks, Gary Hattersley, Mary Bouxsein, & Beate Lanske. (2019). Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Osteoporosis International. 30(8). 1607–1616. 20 indexed citations

Bone, Henry G., Felicia Cosman, Paul D. Miller, et al.. (2018). ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 103(8). 2949–2957. 129 indexed citations

Chandler, Heidi, Beate Lanske, Aurore Varela, et al.. (2018). Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. 120. 148–155. 29 indexed citations

Miller, Paul D., Gary Hattersley, Esther Yuet Ying Lau, et al.. (2018). Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone. 120. 137–140. 44 indexed citations

Yu, Ziyang, Suqin He, Hitisha Patel, et al.. (2017). Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action. Clinical Cancer Research. 23(24). 7608–7620. 23 indexed citations

Bihani, Teeru, Hitisha Patel, Heike Arlt, et al.. (2017). Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clinical Cancer Research. 23(16). 4793–4804. 119 indexed citations

Cosman, Felicia, et al.. (2017). Sustained Fracture Risk Reduction with Sequential Abaloparatide/Alendronate: Results of ACTIVExtend. Journal of Bone and Mineral Research. 32. 2 indexed citations

10.

Varela, Aurore, et al.. (2016). One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. Journal of Bone and Mineral Research. 32(1). 24–33. 59 indexed citations

11.

Vries, Elisabeth G.E. de, Clasina M. Venema, Andor W.J.M. Glaudemans, et al.. (2016). A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.. Journal of Clinical Oncology. 34(15_suppl). TPS627–TPS627. 3 indexed citations

12.

Harb, Wael A., F. Μ. Garner, Jacqueline McDermott, et al.. (2016). Abstract OT2-01-10: A phase 1 study of RAD1901, a novel, orally available, selective estrogen receptor degrader, for the treatment of ER positive advanced breast cancer. Cancer Research. 76(4_Supplement). OT2–1. 2 indexed citations

13.

Miller, Paul D., Gary Hattersley, Bente Juel Riis, et al.. (2016). Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis. JAMA. 316(7). 722–722. 581 indexed citations breakdown →

14.

Hattersley, Gary, Thomas Dean, Braden Corbin, Hila Bahar, & Thomas J. Gardella. (2015). Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 157(1). 141–149. 214 indexed citations

15.

Leder, Benjamin Z., Louis O’Dea, José Zanchetta, et al.. (2014). Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 100(2). 697–706. 191 indexed citations

16.

Miller, Chris P., et al.. (2010). Synthesis of potent, substituted carbazoles as selective androgen receptor modulators (SARMs). Bioorganic & Medicinal Chemistry Letters. 20(24). 7516–7520. 15 indexed citations

17.

Gamer, Laura W., et al.. (1999). A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos. Developmental Biology. 208(1). 222–232. 148 indexed citations

18.

Hattersley, Gary & Timothy Chambers. (1991). Effects of transforming growth factor β1 on the regulation of osteoclastic development and function. Journal of Bone and Mineral Research. 6(2). 165–172. 64 indexed citations

19.

Hattersley, Gary, J. Owens, Adrienne M. Flanagan, & T.J. Chambers. (1991). Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro. Biochemical and Biophysical Research Communications. 177(1). 526–531. 116 indexed citations

20.

Hattersley, Gary & T.J. Chambers. (1989). Calcitonin Receptors as Markers for Osteoclastic Differentiation: Correlation between Generation of Bone-Resorptive Cells and Cells that Express Calcitonin Receptors in Mouse Bone Marrow Cultures*. Endocrinology. 125(3). 1606–1612. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact